A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00141661 |
Recruitment Status
:
Completed
First Posted
: September 1, 2005
Last Update Posted
: August 20, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer Disease | Drug: PF-04494700 - Low Dose Arm Drug: PF-04494700 - High Dose Arm Drug: Placebo Comparator | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 67 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 |
Study Start Date : | October 2005 |
Actual Primary Completion Date : | June 2006 |
Actual Study Completion Date : | June 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: Low Dose Arm |
Drug: PF-04494700 - Low Dose Arm
30 mg loading dose for 6 days, followed by 10 mg daily
|
Experimental: High Dose Arm |
Drug: PF-04494700 - High Dose Arm
60 mg loading dose for 6 days, followed by 20 mg daily
|
Placebo Comparator: Placebo Control |
Drug: Placebo Comparator
Matching placebo.
|
- Safety Measures include Adverse Events [ Time Frame: Every Visit ]
- Laboratory Tests [ Time Frame: Every Office Visit ]
- 12-Lead Electrocardiogram [ Time Frame: Every Office Visit ]
- 24-Hour 12-Lead Serial ECGs [ Time Frame: Baseline, Study End ]
- Surrogate Efficacy Markers in Plasma: A-Beta, C-Reactive Protein, IL-1, IL-6, Isoprostanes, TNF-alpha, TNF-beta [ Time Frame: Baseline, Visit 5, Study End ]
- Cognitive Function Tests: ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL [ Time Frame: Screening Visit, Baseline, Study End ]
- Pharmacokinetic Profile [ Time Frame: Baseline and Every Office Visit ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of probably Alzheimer's disease for at least 1 year.
- Mini Mental State Exam (MMSE) score between 12-26 at screening.
- Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.
Exclusion Criteria:
- Current evidence of a neurological or psychiatric illness that could contribute to dementia.
- Living alone.
- Poorly controlled high blood pressure.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00141661
United States, Arizona | |
Pfizer Investigational Site | |
Sun City, Arizona, United States, 85351 | |
United States, California | |
Pfizer Investigational Site | |
Fresno, California, United States, 93720 | |
Pfizer Investigational Site | |
San Diego, California, United States, 92103 | |
Pfizer Investigational Site | |
San Francisco, California, United States, 94118 | |
United States, Florida | |
Pfizer Investigational Site | |
Fort Lauderdale, Florida, United States, 33321 | |
Pfizer Investigational Site | |
Fort Myers, Florida, United States, 33912 | |
Pfizer Investigational Site | |
Hallandale Beach, Florida, United States, 33009 | |
Pfizer Investigational Site | |
Jacksonville, Florida, United States, 32216 | |
Pfizer Investigational Site | |
Largo, Florida, United States, 33773 | |
Pfizer Investigational Site | |
Orlando, Florida, United States, 32806 | |
Pfizer Investigational Site | |
West palm Beach, Florida, United States, 33407 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Memphis, Tennessee, United States, 38119 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Additional Information:
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT00141661 History of Changes |
Other Study ID Numbers: |
B0341008 TTP488-201 |
First Posted: | September 1, 2005 Key Record Dates |
Last Update Posted: | August 20, 2009 |
Last Verified: | August 2009 |
Keywords provided by Pfizer:
Interventional, Alzheimer, Safety and Tolerability |
Additional relevant MeSH terms:
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |